SciClone on hold by Jefferies

Jefferies & Co., Inc. analyst Adam Walsh rated SciClone Pharmaceuticals, Inc. at hold with a $2.50 price target. The company reported a third-quarter loss per share of $0.03, which was 2 cents above both the analyst's estimate and Street consensus. Look for full Zadaxin phase 2 results in malignant melanoma in the fourth-quarter 2006. Shares of the San Mateo, Calif.-based biotechnology company were up 5 cents, or 2.02%, at $2.53. (Nasdaq: SCLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.